Report Highlights

The U.S. Position in the Global OCT Supply Chain

The United States occupies a dual role in the global optical coherence tomography supply chain — functioning simultaneously as the world's largest end-use market and as a high-value technology development and manufacturing hub. U.S.-based institutions, including Massachusetts General Hospital and the University of California San Diego, have generated foundational OCT patents that underpin global product portfolios. While core optical components such as superluminescent diodes, fiber couplers, and swept-source laser modules are predominantly sourced from Japan, Germany, and South Korea, final system integration, software development, and FDA-cleared product assembly frequently occur on U.S. soil. Optovue's Fremont, California facility and Carl Zeiss Meditec's Dublin, California operations represent significant domestic integration nodes.

On the import side, the U.S. absorbs finished OCT systems from Carl Zeiss Meditec's German manufacturing base, Topcon's Japanese production lines, and Heidelberg Engineering's Heidelberg facilities. Annual U.S. OCT device imports from Japan alone exceeded USD 180 million in 2023, making Japan the single largest foreign supplier. The U.S. exports OCT software platforms, clinical workflow integration systems, and AI-driven diagnostic modules globally, with exports to the EU, Canada, and Australia representing the dominant outbound trade corridors. This asymmetry — importing hardware, exporting intelligence — defines U.S. comparative advantage in the OCT supply chain.

Growth Drivers for U.S. OCT Trade and Production

Three structural drivers are expanding U.S. OCT production capacity and trade volumes through 2032. First, the aging U.S. population — with 55 million Americans over age 65 by 2025 — is generating sustained demand growth for retinal and glaucoma imaging, directly expanding the installed base of ophthalmic OCT systems at optometry chains including MyEyeDr and EyeCare Partners. This demographic pull is compelling domestic distributors to shorten import cycles from Japanese and German OEMs, with Topcon reporting a 22% increase in U.S. order volume between 2022 and 2024. Second, CMS reimbursement expansion for OCT angiography codes has unlocked cardiology and neurology procurement budgets, broadening the addressable market beyond ophthalmology and stimulating new domestic product development.

Third, the integration of AI-powered diagnostic algorithms into OCT platforms is establishing a new U.S. software export channel. Companies including iHealthScreen and Eyenuk are embedding FDA-cleared AI layers into OCT workflows, creating licensable technology assets sold to international OEMs. This positions U.S. firms as value-added software exporters within a hardware supply chain dominated by Asian and European manufacturers. The net effect is margin improvement for U.S.-headquartered participants without requiring capital-intensive domestic hardware manufacturing scale-up, reinforcing the country's role as an innovation exporter rather than a volume producer.

Supply Chain Risks and Trade Barriers

The U.S. OCT supply chain carries concentrated single-source risk at the optical component level. Superluminescent diode modules, which are essential for spectral-domain OCT systems, are supplied by fewer than six global manufacturers, with Inphenix (California) and Thorlabs (New Jersey) representing the only two U.S.-based producers of commercial scale. Over 70% of precision galvanometer mirror assemblies used in OCT scan engines are sourced from suppliers in Japan and Germany, creating lead time vulnerability when yen or euro appreciation pressures procurement costs. The Section 301 tariffs applied to Chinese optical components under the 2018–2020 trade actions added 7.5–25% landed cost to certain subassembly categories, a burden that domestic system integrators have only partially absorbed through supplier diversification.

Logistics infrastructure gaps represent an additional friction point. The concentration of OCT distribution through a limited number of specialized medical device logistics providers — including Medline and Henry Schein — creates capacity constraints during demand surges, as experienced during the post-COVID ophthalmic clinic reopening wave of 2021–2022. Import clearance delays at U.S. ports of entry for Class II and Class III medical devices, particularly at Los Angeles and New York, add average lead time extensions of 8–14 days versus pre-2020 benchmarks. For time-sensitive clinical procurement, these delays create competitive pressure favoring domestically assembled or warehoused OCT systems over direct factory imports.

Trade and Investment Opportunities in U.S. OCT

The most commercially significant near-term opportunity in U.S. OCT trade is the import substitution of swept-source laser modules. Currently, over 85% of swept-source vertical-cavity surface-emitting laser components used in next-generation OCT systems are sourced from Japanese suppliers including Santec and Axsun Technologies (now part of II-VI). Domestic startups such as Insight Photonic Solutions (Boulder, Colorado) are developing tunable laser alternatives at competitive price points, and early procurement commitments from system integrators would accelerate this substitution. Foreign direct investment into U.S.-based photonics manufacturing — particularly from South Korean and Taiwanese optics firms seeking tariff-advantaged U.S. production — represents a parallel investment opportunity that state economic development agencies in Texas and Arizona are actively pursuing.

On the export side, U.S. OCT manufacturers hold a strong position to expand into underpenetrated markets in the Middle East and Southeast Asia, where rising healthcare infrastructure spending is creating first-time OCT procurement cycles. Regulatory harmonization between the FDA and Gulf Cooperation Council health authorities, formalized under the GCC-FDA Mutual Recognition Framework discussions ongoing since 2022, is set to reduce export certification timelines by an estimated 30–40%. U.S. distributors and OEM partners targeting Saudi Arabia's Vision 2030 healthcare expansion and Indonesia's hospital modernization program should initiate market entry agreements before 2027 to capture first-mover advantages in these high-growth import markets.

Market at a Glance

Leading Market Participants

• Carl Zeiss Meditec
• Heidelberg Engineering
• Topcon Corporation
• Optovue (Visionix)
• Leica Microsystems
• Abbott Laboratories
• Nidek Co., Ltd.
• Thorlabs
• Eyenuk
• Novacyt (NovaBay Diagnostics division)

Regulatory and Trade Policy Environment

OCT devices sold in the U.S. market are regulated by the FDA under 21 CFR Part 886 for ophthalmic devices and 21 CFR Part 870 for cardiovascular diagnostic systems, with Class II clearance via 510(k) being the predominant pathway. The FDA's Digital Health Center of Excellence has issued guidance directly relevant to AI-integrated OCT platforms, requiring software change protocols and predetermined change control plans that add 6–12 months to product iteration cycles. Section 301 tariffs on Chinese-origin optical subassemblies remain in effect as of 2025, with the USTR review process ongoing. These tariffs create a structural cost disadvantage for any OCT manufacturer sourcing precision optics from mainland Chinese suppliers, reinforcing procurement shifts toward Taiwan, Japan, and South Korea.

The U.S. maintains no bilateral free trade agreement with Japan or Germany — the two most critical OCT hardware supply nations — meaning that most-favored-nation tariff rates apply to finished OCT system imports. However, the WTO Information Technology Agreement eliminates tariffs on qualifying optical instruments and measurement devices, covering a meaningful portion of OCT system HS code classifications and partially offsetting the absence of bilateral trade preferences. The Inflation Reduction Act's domestic content provisions, while primarily targeting energy and automotive sectors, have prompted renewed congressional attention to medical device domestic production incentives, with proposed amendments to Section 45X advanced manufacturing credits that cover precision photonics components under active legislative consideration as of early 2025.

U.S. OCT Supply Chain Outlook to 2032

By 2032, the U.S. OCT supply chain will shift from a predominantly import-dependent hardware model toward a hybrid structure featuring greater domestic photonics manufacturing capacity. The CHIPS and Science Act's photonics funding provisions — channeled through organizations including the American Institute for Manufacturing Integrated Photonics (AIM Photonics) in Albany, New York — are expected to bring two to three new U.S.-based optical component fabrication facilities online between 2026 and 2029. These facilities will initially serve defense and telecommunications customers but are designed for dual-use production that includes medical-grade optical subassemblies. The net effect will be a reduction in Japanese and German import dependency for swept-source laser modules from 85% to an estimated 55–60% by 2032.

AI-driven OCT diagnostic platforms will become the dominant U.S. export product category in this market, displacing hardware as the primary value creation mechanism. U.S. firms will increasingly operate as IP licensors and platform providers within a global OCT hardware supply chain still anchored in Asia and Europe. The convergence of OCT with photoacoustic imaging and multiphoton microscopy — areas where U.S. academic institutions hold the strongest patent positions — will generate new product categories that require fresh FDA regulatory pathways, creating both market entry barriers and first-mover advantages for domestically positioned innovators. Trade flows will reorient toward software licensing agreements and clinical AI subscriptions rather than device unit exports, fundamentally transforming how U.S. OCT revenue is recorded in international trade statistics.